1. Home
  2. EBR vs INSM Comparison

EBR vs INSM Comparison

Compare EBR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EBR
  • INSM
  • Stock Information
  • Founded
  • EBR 1962
  • INSM 1988
  • Country
  • EBR Brazil
  • INSM United States
  • Employees
  • EBR N/A
  • INSM N/A
  • Industry
  • EBR Electric Utilities: Central
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • EBR Utilities
  • INSM Health Care
  • Exchange
  • EBR Nasdaq
  • INSM Nasdaq
  • Market Cap
  • EBR 14.8B
  • INSM 12.6B
  • IPO Year
  • EBR N/A
  • INSM 2000
  • Fundamental
  • Price
  • EBR $7.47
  • INSM $68.28
  • Analyst Decision
  • EBR
  • INSM Strong Buy
  • Analyst Count
  • EBR 0
  • INSM 16
  • Target Price
  • EBR N/A
  • INSM $95.36
  • AVG Volume (30 Days)
  • EBR 1.3M
  • INSM 2.7M
  • Earning Date
  • EBR 05-19-2025
  • INSM 05-08-2025
  • Dividend Yield
  • EBR 3.72%
  • INSM N/A
  • EPS Growth
  • EBR 130.56
  • INSM N/A
  • EPS
  • EBR 0.74
  • INSM N/A
  • Revenue
  • EBR $6,496,718,152.00
  • INSM $363,707,000.00
  • Revenue This Year
  • EBR $4.95
  • INSM $30.36
  • Revenue Next Year
  • EBR $10.06
  • INSM $115.55
  • P/E Ratio
  • EBR $8.12
  • INSM N/A
  • Revenue Growth
  • EBR 8.13
  • INSM 19.17
  • 52 Week Low
  • EBR $5.45
  • INSM $21.92
  • 52 Week High
  • EBR $7.93
  • INSM $84.91
  • Technical
  • Relative Strength Index (RSI)
  • EBR 53.66
  • INSM 41.91
  • Support Level
  • EBR $7.61
  • INSM $67.21
  • Resistance Level
  • EBR $7.80
  • INSM $73.39
  • Average True Range (ATR)
  • EBR 0.15
  • INSM 2.59
  • MACD
  • EBR -0.01
  • INSM 0.08
  • Stochastic Oscillator
  • EBR 56.88
  • INSM 26.58

About EBR Centrais Electricas Brasileiras S A (Each representing one Common Share)

Centrais Eletricas Brasileiras SA is engaged in the generation, transmission, and commercialization of electricity in Brazil. The company operates a portfolio of wind, thermal, hydro, and nuclear power plants located throughout the country. Its segments are Generation which consists of the generation of electric energy and the sale of energy to distribution companies and free consumers, and commercialization; Transmission which consists of the transmission of electric energy; and Administration activities mainly represent the Company's cash management, the management of the compulsory loan, and the management of business in SPEs, and others.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: